Skip to Main Content
Skip Nav Destination
Person pricking their finger for a blood glucose test.

Special Edition: Early Identification and Delay of Type 1 Diabetes

 

Sanofi

In this special edition episode, Dr. Neil Skolnik and guest Dr. Jay Shubrook examine the evolving role of primary care in the early detection and delay of type 1 diabetes. They discuss current evidence supporting population-level autoantibody screening, risk stratification approaches, and emerging therapies aimed at preserving β-cell function. As early intervention becomes increasingly feasible, this episode underscores the need for primary care engagement in identifying individuals before clinical onset.

This special edition of Diabetes Core Update is sponsored by an independent educational grant from Sanofi.

Please listen to the episodes by clicking on the podcast player below or by freely subscribing to Diabetes Core Update via Apple Podcasts, Amazon Music, Spotify, or your preferred podcast platform.

Play Episode

Total Time: 26:32 | File Size: 36.8 MB

Episode Notes

In this special episode on Early Identification and Delay of Type 1 Diabetes, Dr. Neil Skolnik discusses this emerging area with Dr. Jay Shubrook. This special episode is supported by an independent educational grant from Sanofi.

Presented by:

Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health

Jay Shubrook, DO, Professor and Director of Diabetes Services, Touro University. Past Chair, The American Diabetes Association Primary Care Advisory Group, Past Chair of the American College of Diabetology.

Webinar Registration (Apr 28, 2025 10:00 AM):

Early Detection Saves Lives: Implementing Type 1 Diabetes Screening in Pediatric and Primary Care

Select references mentioned in the podcast:

Consensus guidance for monitoring individuals with islet autoantibody-positive pre-stage 3 type 1 diabetes. Diabetes Care 2024;47(8):1276–1298

An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. N Engl J Med 2019;381:603-613

Resources for Auto-antibody Testing:

Type 1 Diabetes TrialNet Centers of Excellence Locations

Type 1 Risk test

Trialnet

Diabetes Core Update is a monthly audio podcast devoted to presenting and discussing the latest clinically relevant articles from ADA’s four scholarly journals: Diabetes, Diabetes Care, Clinical Diabetes, and Diabetes Spectrum. Users can freely access previous episodes of Diabetes Core Update here.

For previous episodes, please visit:

Subscribe on iTunes

or Create an Account

Close Modal
Close Modal